Literature DB >> 30815083

Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.

Suruchi Fialoke1, Anders Malarstig1, Melissa R Miller1, Alexandra Dumitriu1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide. NAFLD patients have excessive liver fat (steatosis), without other liver diseases and without excessive alcohol consumption. NAFLD consists of a spectrum of conditions: benign steatosis or non-alcoholic fatty liver (NAFL), steatosis accompanied by inflammation and fibrosis or nonalcoholic steatohepatitis (NASH), and cirrhosis. Given a lack of clinical biomarkers and its asymptomatic nature, NASH is under-diagnosed. We use electronic health records from the Optum Analytics to (1) identify patients diagnosed with benign steatosis and NASH, and (2) train machine learning classifiers for NASH and healthy (non-NASH) populations to (3) predict NASH disease status on patients diagnosed with NAFL. Summarized temporal lab data for alanine aminotransferase, aspartate aminotransferase, and platelet counts, with basic demographic information and type 2 diabetes status were included in the models.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30815083      PMCID: PMC6371264     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  18 in total

1.  Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record.

Authors:  Kathleen E Corey; Uri Kartoun; Hui Zheng; Stanley Y Shaw
Journal:  Dig Dis Sci       Date:  2015-11-04       Impact factor: 3.199

2.  Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease.

Authors:  Kathleen E Corey; Uri Kartoun; Hui Zheng; Raymond T Chung; Stanley Y Shaw
Journal:  Am J Gastroenterol       Date:  2016-03-01       Impact factor: 10.864

3.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

4.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

Review 5.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

Review 6.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

7.  Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies.

Authors:  A Katrina Loomis; Shaum Kabadi; David Preiss; Craig Hyde; Vinicius Bonato; Matthew St Louis; Jigar Desai; Jason M R Gill; Paul Welsh; Dawn Waterworth; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

8.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

Authors:  Robert J Wong; Ramsey Cheung; Aijaz Ahmed
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

Review 9.  Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease.

Authors:  Mark Cc Cheah; Arthur J McCullough; George Boon-Bee Goh
Journal:  J Clin Transl Hepatol       Date:  2017-06-24

10.  Metabolic profiling of fatty liver in young and middle-aged adults: Cross-sectional and prospective analyses of the Young Finns Study.

Authors:  Jari E Kaikkonen; Peter Würtz; Emmi Suomela; Miia Lehtovirta; Antti J Kangas; Antti Jula; Vera Mikkilä; Jorma S A Viikari; Markus Juonala; Tapani Rönnemaa; Nina Hutri-Kähönen; Mika Kähönen; Terho Lehtimäki; Pasi Soininen; Mika Ala-Korpela; Olli T Raitakari
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

View more
  9 in total

Review 1.  The digital transformation of hepatology: The patient is logged in.

Authors:  Tiffany Wu; Douglas A Simonetto; John D Halamka; Vijay H Shah
Journal:  Hepatology       Date:  2022-01-31       Impact factor: 17.298

2.  Multimodal NASH prognosis using 3D imaging flow cytometry and artificial intelligence to characterize liver cells.

Authors:  Ramkumar Subramanian; Rui Tang; Zunming Zhang; Vaidehi Joshi; Jeffrey N Miner; Yu-Hwa Lo
Journal:  Sci Rep       Date:  2022-07-01       Impact factor: 4.996

3.  Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis.

Authors:  Matt Docherty; Stephane A Regnier; Gorana Capkun; Maria-Magdalena Balp; Qin Ye; Nico Janssens; Andreas Tietz; Jürgen Löffler; Jennifer Cai; Marcos C Pedrosa; Jörn M Schattenberg
Journal:  J Am Med Inform Assoc       Date:  2021-06-12       Impact factor: 4.497

4.  Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.

Authors:  Sina Ghandian; Rahul Thapa; Anurag Garikipati; Gina Barnes; Abigail Green-Saxena; Jacob Calvert; Qingqing Mao; Ritankar Das
Journal:  JGH Open       Date:  2022-03-08

5.  Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH).

Authors:  Ozge Yasar; Patrick Long; Brett Harder; Hanna Marshall; Sanjay Bhasin; Suyin Lee; Mark Delegge; Stephanie Roy; Orla Doyle; Nadea Leavitt; John Rigg
Journal:  BMJ Health Care Inform       Date:  2022-03

6.  Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study.

Authors:  Jin Ge; Mark J Pletcher; Jennifer C Lai
Journal:  Gastroenterology       Date:  2021-07-18       Impact factor: 33.883

7.  Outcomes of SARS-CoV-2 Infection in Patients with Chronic Liver Disease and Cirrhosis: a N3C Study.

Authors:  Jin Ge; Mark J Pletcher; Jennifer C Lai
Journal:  medRxiv       Date:  2021-06-07

8.  Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.

Authors:  Marina Serper; Marijana Vujkovic; David E Kaplan; Rotonya M Carr; Kyung Min Lee; Qing Shao; Donald R Miller; Peter D Reaven; Lawrence S Phillips; Christopher J O'Donnell; James B Meigs; Peter W F Wilson; Rachel Vickers-Smith; Henry R Kranzler; Amy C Justice; John M Gaziano; Sumitra Muralidhar; Saiju Pyarajan; Scott L DuVall; Themistocles L Assimes; Jennifer S Lee; Philip S Tsao; Daniel J Rader; Scott M Damrauer; Julie A Lynch; Danish Saleheen; Benjamin F Voight; Kyong-Mi Chang
Journal:  PLoS One       Date:  2020-08-25       Impact factor: 3.240

9.  A Noninvasive Risk Stratification Tool Build Using an Artificial Intelligence Approach for Colorectal Polyps Based on Annual Checkup Data.

Authors:  Chieh Lee; Tsung-Hsing Lin; Chen-Ju Lin; Chang-Fu Kuo; Betty Chien-Jung Pai; Hao-Tsai Cheng; Cheng-Chou Lai; Tsung-Hsing Chen
Journal:  Healthcare (Basel)       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.